A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlaxoSmithKline
Age
40–99
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
COPD diagnosis
At least 10 pack year smoking history
Post-albuterol FEV1 greater than or equal to 40% to less than or equal to 80% of predicted normal
An FEV1/FVC ratio of less than or equal to 0.70
You may not be if
Current diagnosis of asthma
Other respiratory disorder other than COPD
Abnormal and clinical significant ECG
Chest x-ray clinically significant abnormality not believed to be due to COPD
Body Mass Index of greater than or equal to 40/kg/m2
Use of Long Term Oxygen Therapy
Lung resection surgery
Women pregnant or lactating at Visit 1
Previously diagnosed cancer unless in complete remission for 2 years at Visit 1
Clareo Health | A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
